BridgeBio Pharma, Inc. (BBIO)
| Market Cap | 15.11B +25.1% |
| Revenue (ttm) | 945.54M +167.3% |
| Net Income | -592.13M |
| EPS | -3.04 |
| Shares Out | 194.80M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,601,223 |
| Open | 74.58 |
| Previous Close | 74.29 |
| Day's Range | 73.49 - 78.00 |
| 52-Week Range | 62.06 - 93.42 |
| Beta | 0.94 |
| Analysts | Buy |
| Price Target | 106.85 (+37.78%) |
| Earnings Date | Oct 29, 2026 |
About BBIO
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective ... [Read more]
Financial Performance
In 2025, BridgeBio Pharma's revenue was $502.08 million, an increase of 126.26% compared to the previous year's $221.90 million. Losses were -$724.93 million, 35.3% more than in 2024.
Financial StatementsAnalyst Summary
According to 22 analysts, the average rating for BBIO stock is "Buy." The 12-month stock price target is $106.85, which is an increase of 37.78% from the latest price.
News
BridgeBio to Participate in November and December Investor Conferences
PALO ALTO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on develo...
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic condi...
BridgeBio to Present New Acoramidis Data on Heart Failure Events in ATTR-CM at the American Heart Association Scientific Sessions 2026
PALO ALTO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on develo...
BridgeBio Pharma price target raised to $108 from $106 at Canaccord
Canaccord raised the firm’s price target on BridgeBio Pharma (BBIO) to $108 from $106 and keeps a Buy rating on the shares. The firm said they reported 3Q26 results that…
BridgeBio Pharma price target raised to $88 from $87 at Morgan Stanley
Morgan Stanley analyst Sean Laaman raised the firm’s price target on BridgeBio Pharma (BBIO) to $88 from $87 and keeps an Overweight rating on the shares.
BridgeBio Pharma price target lowered to $100 from $110 at TD Cowen
TD Cowen lowered the firm’s price target on BridgeBio Pharma (BBIO) to $100 from $110 and keeps a Buy rating on the shares. The firm said Attruby Q3 US sales…
BridgeBio Pharma Earnings Call Transcript: Q3 2026
Q3 revenue reached $353.2 million, including a one-time $75 million milestone, as Attruby grew 134% YoY. Three launches are planned within seven months, supported by $1.5 billion in cash and marketable securities.
BridgeBio Pharma Earnings release: Q3 2026
BridgeBio Pharma released its Q3 2026 earnings on October 29, 2026, summarizing the period's financial results.
BridgeBio Pharma Quarterly report: Q3 2026
BridgeBio Pharma has published its Q3 2026 quarterly earnings report on October 29, 2026.
BridgeBio Pharma reports Q3 EPS (42c), consensus (56c)
Reports Q3 revenue $353.17M, consensus $295.75M. “Attruby delivered another quarter of sequential growth, driven by continued gains in first-line share, and the real-world evidence emerging across ind...
BridgeBio Reports Third Quarter 2026 Financial Results and Corporate Updates
- $353.2 million in total third quarter revenues, primarily comprised of $253.2 million of U.S. Attruby net product revenue (up approximately $31 million sequentially and $145 million year over year)....
BridgeBio Pharma Slides: Corporate presentation
BridgeBio Pharma has posted slides in relation to its latest quarterly earnings report, which was published on October 29, 2026.
BridgeBio to Report Third Quarter 2026 Financial Results and Commercial Updates on October 29, 2026 at 4:30 pm ET
PALO ALTO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic condi...
BridgeBio Pharma price target lowered to $87 from $97 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on BridgeBio Pharma (BBIO) to $87 from $97 and keeps an Overweight rating on the shares.
BridgeBio Pharma price target lowered to $102 from $104 at BofA
BofA analyst Jason Zemansky lowered the firm’s price target on BridgeBio Pharma (BBIO) to $102 from $104 and keeps a Buy rating on the shares. The firm updated estimates ahead…
BridgeBio Pharma price target raised to $120 from $115 at Piper Sandler
Piper Sandler raised the firm’s price target on BridgeBio Pharma (BBIO) to $120 from $115 and keeps an Overweight rating on the shares. Ahead of Q3 2026 earnings for the…
BridgeBio Pharma price target lowered to $91 from $94 at Citi
Citi lowered the firm’s price target on BridgeBio Pharma (BBIO) to $91 from $94 and keeps a Neutral rating on the shares. The firm updated the company’s model ahead the…
BridgeBio Pharma assumed with a Buy at UBS
UBS assumed coverage of BridgeBio Pharma (BBIO) with a Buy rating with a price target of $92, up from $82. The Street underestimates the company’s lead drug Attruby commercial potential…
BridgeBio announces real-world evidence, Phase 3 ATTRibute CM sub-analyses
BridgeBio Pharma (BBIO) announced that new, independent and contemporary real-world evidence as well as Phase 3 ATTRibute-CM sub-analyses of acoramidis in transthyretin amyloid cardiomyopathy, ATTR-CM...
BridgeBio Pharma presents results from Phase 3 CALIBRATE trial of encaleret
BridgeBio Pharma (BBIO) presented bone turnover results and patient-reported outcomes from the Phase 3 CALIBRATE trial of encaleret in autosomal dominant hypocalcemia type 1, ADH1. The data were prese...
BridgeBio Pharma price target lowered to $156 from $157 at Barclays
Barclays lowered the firm’s price target on BridgeBio Pharma (BBIO) to $156 from $157 and keeps an Overweight rating on the shares. The firm expects another quarter of steady strength…
BridgeBio to Present New Acoramidis Data, Including Independent Comparative Real-World EHR Data at the HFSA Annual Scientific Meeting 2026
PALO ALTO, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on develo...
BridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual Meeting
PALO ALTO, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on develo...
BridgeBio Pharma announces FDA acceptance of oral infigratinib NDA
BridgeBio Pharma (BBIO) announced the FDA has accepted for filing its new drug application, or NDA, with Priority Review for oral infigratinib for the treatment of children with achondroplasia. The…
BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia
- Accepted for Priority Review with a PDUFA target action date of February 4, 2027; being granted Priority Review by the FDA underscores the significant unmet need for an oral targeted therapeutic opt...